# Semaglutide SUSTAIN-6: heart outcomes in type 2 diabetes

Source: https://pepvault.app/research/semaglutide-sustain-6-2016

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Semaglutide](https://pepvault.app/research#semaglutide)

Randomized trial · people

# Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In people with type 2 diabetes and high heart risk, semaglutide did not add heart risk and had fewer combined heart and stroke events than placebo, though eye complications rose.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 3297
- **Published:** 2016
- **Journal:** N Engl J Med

## What they tested

Does weekly semaglutide raise the risk of major heart and stroke events in people with type 2 diabetes, compared with placebo?

## How the study was done

A randomized, placebo-controlled trial in 3297 people with type 2 diabetes on standard care, given once-weekly semaglutide (0.5 mg or 1.0 mg arms) or placebo (an inactive look-alike treatment) for 104 weeks. The main goal was to show semaglutide was no worse than placebo (noninferiority), and 83.0% already had heart disease, kidney disease or both.

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

The combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke happened in 108 of 1648 people (6.6%) on semaglutide and 146 of 1649 (8.9%) on placebo, a hazard ratio (relative risk over time) of 0.74 (95% CI 0.58 to 0.95). Nonfatal stroke was lower at 1.6% vs 2.7% (hazard ratio 0.61); nonfatal heart attack was 2.9% vs 3.9% (hazard ratio 0.74, P=0.12, not significant); and cardiovascular death rates were similar. New or worsening kidney disease was less common on semaglutide, but serious eye complications from diabetic retinopathy (such as bleeding in the eye or blindness) were more common, with a hazard ratio of 1.76. Serious adverse events were fewer on semaglutide, but more people stopped treatment because of side effects, mostly stomach and gut problems.

## What it doesn’t show

The trial was designed to rule out harm (noninferiority), not to prove benefit, it lasted 104 weeks, and most people had high cardiovascular risk. It was funded by Novo Nordisk.

## The paper

Marso et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016.

- [PubMed (PMID 27633186)](https://pubmed.ncbi.nlm.nih.gov/27633186/)
- [The paper (DOI 10.1056/NEJMoa1607141)](https://doi.org/10.1056/NEJMoa1607141)
- [ClinicalTrials.gov (NCT01720446)](https://clinicaltrials.gov/study/NCT01720446)

## The compound

- [Semaglutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

## With this study

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [All 20 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Semaglutide

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026) Randomized trial · people · 2026
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026) Randomized trial · people · 2026
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026) Randomized trial · people · 2026
- [Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes](https://pepvault.app/research/semaglutide-adjust-t1d-2025) Randomized trial · people · 2025
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025) Randomized trial · people · 2025
- [Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks](https://pepvault.app/research/semaglutide-sanyal-2025) Randomized trial · people · 2025
- [Every study on Semaglutide](https://pepvault.app/research#semaglutide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Mixing charts

- [2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [All 20 studies](https://pepvault.app/research#semaglutide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Semaglutide](https://pepvault.app/research#semaglutide)

## The library

- [Semaglutide](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
